Anzeige
Mehr »
Mittwoch, 10.12.2025 - Börsentäglich über 12.000 News
Neuer Lithium-Schock: China-Mine bleibt dicht - Lithiumpreise explodieren
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1JWL4 | ISIN: NO0010598683 | Ticker-Symbol: HBQ
Frankfurt
10.12.25 | 08:01
0,104 Euro
0,00 % 0,000
1-Jahres-Chart
HOFSETH BIOCARE ASA Chart 1 Jahr
5-Tage-Chart
HOFSETH BIOCARE ASA 5-Tage-Chart
RealtimeGeldBriefZeit
0,1050,15408:32

Aktuelle News zur HOFSETH BIOCARE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
HOFSETH BIOCARE Aktie jetzt für 0€ handeln
03.12.Hofseth BioCare ASA: Financial calendar-
21.11.Hofseth BioCare ASA: PRIMARY INSIDER NOTIFICATION3
21.11.Hofseth BioCare ASA: RESULTS OF SUBSEQUENT OFFERING2
20.11.Hofseth BioCare ASA: Extraordinary General Meeting completed2
20.11.Hofseth BioCare ASA: LAST DAY OF SUBSCRIPTION PERIOD IN SUBSEQUENT OFFERING3
20.11.Hofseth BioCare ASA: HBC ANNOUNCES STRATEGIC PRODUCT PARTNERSHIP WITH JAMES LAVALLE & METABOLIC ELITE-
10.11.Hofseth BioCare ASA: Publication of the Prospectus - Start of the Subscription Period for the Subsequent Offering2
07.11.Hofseth BioCare ASA: Terms of the Subsequent Offering-
07.11.Hofseth Biocare ASA: Third Quarter 2025 Financial Report107HBC recorded total operating revenues of NOK 54.9 million in the third quarter of 2025, compared to NOK 67.9 million in the same period last year. Net operating revenues were NOK 54.8 million, reflecting...
► Artikel lesen
30.10.Hofseth BioCare ASA: NOTICE OF EXTRAORDINARY GENERAL MEETING3
28.10.XFRA CAPITAL ADJUSTMENT INFORMATION - 28.10.2025208Das Instrument 5YW CA07135M2031 BATTERY X METALS INC. EQUITY wird ex Kapitalmassnahme gehandelt am 28.10.2025 The instrument 5YW CA07135M2031 BATTERY X METALS INC. EQUITY is traded ex capital adjustment...
► Artikel lesen
27.10.Hofseth BioCare ASA: Mandatory Notification of Trade2
27.10.Hofseth Biocare ASA: Ex. Subsequent Offering Today2
27.10.Hofseth BioCare ASA: Key Information Relating to Subsequent Offering2
27.10.Hofseth BioCare ASA: Private placement successfully placed7
27.10.Hofseth BioCare ASA: Disclosures of Large Shareholdings3
24.10.Hofseth Biocare ASA: USD 5 Million Divestment in Aecorbio146NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION...
► Artikel lesen
24.10.Hofseth BioCare ASA: Contemplated Private Placement and Partial Divestment of Shares in Aecorbio323NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION...
► Artikel lesen
17.09.Hofseth Biocare ASA: AECORBIO SECURES A FURTHER $1.5M AT A $30M VALUATION FOR ONGOING FT-002A PEPTIDE DEVELOPMENT IN PROSTATE CANCER9
09.09.Hofseth Biocare ASA: ProGo, the world's first consumer health GLP-1 & GIP receptor agonist with muscle mass protection via inhibition of Myostatin and Activin A pathways132HBC has today released a whitepaper demonstrating how its bioactive peptide ingredient ProGo® uniquely provides complete GLP-1 support. To maximize the effect of GLP-1 therapy, lean muscle mass needs...
► Artikel lesen
Weiter >>
26 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1